Recent developments in the pharmaceutical treatment of one of the deadliest viral diseases - Hepatitis C - finally received approval from the Ministry of Health. Thereafter, significant changes were made formally in the instructions in the Simeprevir drug used to treat chronic hepatitis C genotype first. This means in combination with another specific drug - sofosbuvir - recommended for treatment of patients (only adults under age) with compensated liver disease (including cirrhosis without co-infection with HIV), which previously received no treatment or received, but the previous therapy was insufficient effective.
Experts note: Simeprevira of use in combination with the original sofosbuvir say a real breakthrough in the treatment of chronic hepatitis C.
To date, this form of hepatitis C (ie chronic) - one of the most common infectious diseases in the world. Every year, the virus "reaches out" to 3 or even 4 million people around the world, and about 150 million of them are the chronically ill, and thus at serious risk (more likely) the development of cirrhosis liver.
Simeprevir - the so-called second wave protease inhibitor with proven clinical effect, which infected the patient should be taken every 24 hours. Drug treat different groups of patients with chronic hepatitis C, including those with compensated cirrhosis. The means available in gelatine capsules, each of which contains a daily dose of medication, the locking protease enzyme action, allowing the hepatitis C virus to survive and reproduce in infected cells.
Therapy with this drug in combination with sofosbuvir - it is confirmed by studies of the method, leading to a complete cure of patients with chronic hepatitis C genotype first. And yet it is the only approved bezinterferonovaya scheme without NS5A-inhibitor. And its effectiveness does not depend on ribavirin.
Russian experts suggest that ministerial approval of a combination of drugs and Simeprevir sofosbuvir for treatment - a completely new and definitely significant word in the treatment of hepatitis C. After this point the efficiency regimens of the disease is no longer dependent on the interferon. And this is very important.
Want to know more about medicine? Do not forget to support our channel in service Yandex. Zen Like and subscription. It motivates us to publish more interesting materials. Also, you can quickly learn about new publications.
